These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22607214)

  • 41. [Brain natriuretic peptide in acute coronary syndromes: utility of NT-pro BNP assay].
    Ollivier JP; Revel F
    Bull Acad Natl Med; 2004; 188(9):1529-38; discussion 1538-40. PubMed ID: 15997622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of cardiac biomarkers in end-stage renal disease.
    Wang AY; Lai KN
    J Am Soc Nephrol; 2008 Sep; 19(9):1643-52. PubMed ID: 18322158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B-type natriuretic peptide in heart failure.
    Moe GW
    Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease.
    Mark PB; Stewart GA; Gansevoort RT; Petrie CJ; McDonagh TA; Dargie HJ; Rodger RS; Jardine AG
    Nephrol Dial Transplant; 2006 Feb; 21(2):402-10. PubMed ID: 16221702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. N-terminal pro-brain natriuretic peptide and outcomes in patients undergoing surgical ventricular restoration.
    Ballotta A; Ranucci M; Kunkl A; El Baghdady H; Bossone E; Castelvecchio S; Frigiola A; Menicanti L; Di Donato M; Mehta RH
    Am J Cardiol; 2010 Mar; 105(5):640-4. PubMed ID: 20185010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive role of BNP and NT-proBNP in hemodialysis patients.
    Sun L; Sun Y; Zhao X; Xu C; Chen D; Li L; Ma Y; Rong S; Mei C
    Nephron Clin Pract; 2008; 110(3):c178-84. PubMed ID: 18957868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aminoterminal B-type natriuretic peptide (NT-proBNP) in end-stage renal failure patients on regular hemodialysis: does it have diagnostic and prognostic implications?
    Pimenta J; Sampaio F; Martins P; Carvalho B; Rocha-Gonçalves F; Ferreira A; Bettencourt P
    Nephron Clin Pract; 2009; 111(3):c182-8. PubMed ID: 19194108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
    Desai AS; Toto R; Jarolim P; Uno H; Eckardt KU; Kewalramani R; Levey AS; Lewis EF; McMurray JJ; Parving HH; Solomon SD; Pfeffer MA
    Am J Kidney Dis; 2011 Nov; 58(5):717-28. PubMed ID: 21820220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pro-B-type natriuretic peptide levels in acute decompensated heart failure.
    Waldo SW; Beede J; Isakson S; Villard-Saussine S; Fareh J; Clopton P; Fitzgerald RL; Maisel AS
    J Am Coll Cardiol; 2008 May; 51(19):1874-82. PubMed ID: 18466803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Impact of acute fluid restriction on levels of natriuretic peptides in patients on a chronic dialysis program].
    Oral I; Stejskal D; Loucký J; Sislák Z; Coufal Z; Mistrík J; Náplava R
    Vnitr Lek; 2004 Nov; 50(11):812-7. PubMed ID: 15648959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes.
    Wiviott SD; de Lemos JA; Morrow DA
    Clin Chim Acta; 2004 Aug; 346(2):119-28. PubMed ID: 15256312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The usefulness of natriuretic peptides measurements in the diagnostics of chosen cardiovascular diseases].
    Grzywa-Celińska A; Celiński R; Kwaśniewska K; Dyczko M; Prystupa A; Mosiewicz J
    Pol Merkur Lekarski; 2013 Apr; 34(202):232-4. PubMed ID: 23745332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease.
    Yang WL; Fahim M; Johnson DW
    Clin Biochem; 2020 Sep; 83():1-11. PubMed ID: 32511964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical value of natriuretic peptides in chronic kidney disease.
    Santos-Araújo C; Leite-Moreira A; Pestana M
    Nefrologia; 2015; 35(3):227-33. PubMed ID: 26299165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brain natriuretic peptide in peritoneal dialysis patients.
    Haapio M; Honkanen E; Ronco C
    Contrib Nephrol; 2009; 163():110-116. PubMed ID: 19494603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Physiology and clinical role of natriuretic peptides].
    Szabó G; Rigó J; Nagy B
    Orv Hetil; 2011 Jun; 152(26):1025-34. PubMed ID: 21652296
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases.
    Battistoni A; Rubattu S; Volpe M
    Int J Cardiol; 2012 May; 157(2):160-8. PubMed ID: 21763018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Natriuretic peptides in aortic stenosis.
    Torres-Ramalho P; Araújo JP; Bettencourt P; Moura LM
    Rev Port Cardiol; 2012 Oct; 31(10):655-60. PubMed ID: 22980570
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are natriuretic peptides useful biomarkers in dialysis patients?
    van den Kerkhof JJ; Van der Sande FM; Leunissen K; Kooman JP
    Perit Dial Int; 2007; 27(6):636-40. PubMed ID: 17984422
    [No Abstract]   [Full Text] [Related]  

  • 60. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.
    Motiwala SR; Januzzi JL
    Clin Pharmacol Ther; 2013 Jan; 93(1):57-67. PubMed ID: 23187878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.